{‘She lacks no expertise’: this US scientific community girds for Dr. Høeg's role at the Food and Drug Administration.

Given that America undertakes historic revisions to its immunization guidelines, an unexpected name appears in a surprising turn: Høeg, a Danish American sports medicine doctor and epidemiologist who rose to prominence by expressing skepticism about coronavirus shots during the global health crisis and has concentrated on potential deaths following Covid vaccination in her short time at the Food and Drug Administration.

Proposed Changes to Childhood Immunization Program

Agency leaders were set to unveil radical changes to the pediatric vaccination calendar recently, bringing the US with Denmark’s immunization schedule, sources say – a major change that would place the US out of step with much of the world with no evidence for public health gain. The announcement has been delayed until the coming year.

In place of the director of the vaccine center, Høeg is scheduled to address the audience at the gathering. She was newly appointed interim head of the FDA’s CDER, the fifth individual to lead the center this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position might represent a closer partnership between the pharmaceutical and biologics centers as Dr. Høeg and Prasad solidify control at the regulatory agency – and it points to a increased emphasis upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has often pushed for ending certain pediatric vaccine recommendations in the US so as to align more like Denmark, a nation with nationalized medicine and a citizenry roughly the population of the state of Wisconsin.

In her initial public appearances, she has kept her attention on vaccines – traditionally the domain of Prasad, head of the FDA’s vaccine center – as opposed to medication approval.

Concerns Over Expertise

The appointee has no apparent background in pharmaceutical research, regulation or management, which has been standard for past heads of the CBER. She has been employed at the FDA as a key advisor to the commissioner and the vaccine center since March.

“She doesn’t seem to have the necessary background” for running the CDER, remarked Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in managing a large organization. She has no expertise in industry regulation.”

Previous directors of the center would “be deeply familiar with legal statutes and the science of pharmaceutical innovation”, commented Janet Woodcock. “Frankly, she has not acquired the sort of resume that previous people who ran CBER have had.”

This division has an enormous range of responsibilities at the agency, Woodcock emphasized.

“The public just focuses on the novel medication approvals, but the generic drug division clears a multitude of generic medications. There is also a biosimilars program, OTC medication office and more, and all of those have to be supervised,” she explained. “The responsibility you neglect, that is precisely what that I always told people is going to cause problems.”

There is also, a major administrative aspect to the role, which oversees more than 5,000 employees. “It’s a massive administrative position, if you perform it correctly,” the former official concluded.

Agency Reaction and Contentious Initiatives

When asked about inquiries about Dr. Høeg's credentials and whether this selection signifies increased cooperation among regulatory chiefs on vaccines, a representative said that the “inquiries rely on inaccurate assumptions”.

“Her experience matches the functions of her position,” the spokesperson said, noting the time Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and shot safety tracking”.

In her interim role, Dr. Høeg inherits the agency head's recently launched priority voucher program, a disputed expedited therapy clearance system that reportedly troubled her preceding directors. “How are these therapies being picked for this expedited pathway? Who is making the decisions?” Dr. Howard questioned. “There’s a lot of lack of transparency going on at the FDA right now.”

In general, he said, “the agency seems to be moving towards laxer oversight of most medications, except for vaccines.”

Public History on Vaccines

Regarding immunizations, Høeg has a more documented, if troubling, past, some experts observe. She published a research paper using unconfirmed public submissions to determine the rate of myocarditis following COVID-19 vaccination. She consulted for the state of Florida top health official Dr. Joseph Ladapo, who was said to have modified findings to imply COVID-19 vaccinations are pose a greater threat than they are.

Among her “wish list” for the new administration encompassed changing guidelines for novel immunizations and ending “unnecessary” immunizations, she stated following the vote on a podcast. At the agency, Høeg has reportedly floated the idea of barring teenage boys from receiving Covid vaccines.

“She’s an thorough true believer who commences with her beliefs and works backwards to fit the evidence in a very disingenuous, dishonest way,” Howard argued.

Gaining Influence and a “Revenge Tour”

Høeg joined fellow skeptics, {like|